Asthma :: Even occasional use of spray cleaners may cause asthma in adults

Using household cleaning sprays and air fresheners as little as once a week can raise the risk of developing asthma in adults, say researchers in Europe. Such products have been associated with increased asthma rates in cleaning professionals, but a similar effect in nonprofessional users has never before been shown.

Cough :: Guidelines for parents when treating children with cough & cold medicines

Nonprescription Drug Manufacturers Association of Canada – NDMAC and its member companies are committed to working with Health Canada toward to ensure the safety and efficacy of cough and cold medicines for children. NDMAC understands that Canadian parents may be concerned about how they should proceed when their children suffer from the symptoms of coughs and colds.

Sickle Cell Disease :: Anticlotting drug found to be safe in sickle cell patients

An intravenous “blood thinner” widely used in patients with acute coronary syndromes and during coronary artery stent placement appears to be safe in patients with sickle cell disease and may have beneficial anti-inflammatory effects, a small study at the University of North Carolina at Chapel Hill School of Medicine has found.

Oxygen Therapy :: 1st successful treatment for chronic TBI

A research team led by Dr. Paul Harch, Assistant Professor of Clinical Medicine at Louisiana State University Health Sciences Center New Orleans and Director of the LSU Hyperbaric Medicine Fellowship Program, has published findings that show hyperbaric oxygen therapy improved spatial learning and memory in a model of chronic traumatic brain injury.

Multiple Sclerosis :: Accentia announces investigational new drug application for Revimmune for refractory MS

Accentia Biopharmaceuticals announces that it met with the Food and Drug Administration (FDA) on September_26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune™. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase 3 randomized controlled, multi-center clinical trial of Revimmune, the company’s potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis (MS).

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack